This review demonstrates that local injection of botulinum toxins can alleviate neuropathic pain experienced at the site of surgery and radiation in cancer patients. Local injection of botulinum neurotoxins can also heal fistula and sialocele in the parotid gland of cancer patients damaged by surgical trauma and radiation.

1. Introduction {#sec1-toxins-12-00032}
===============

Currently, there are vast indications for the use of botulinum neurotoxins (BoNT) type A and B in clinical medicine. Their specific inhibitory action on cholinergic synapses makes them desirable for the treatment of several hyperkinetic movement disorders as well as symptoms caused by glandular hyperactivity (sialorrhea and hyperhidrosis) and bladder dysfunction \[[@B1-toxins-12-00032]\]. Disease-oriented reviews indicate that these agents are frequently used for the treatment of spasticity in several common disease conditions such as stroke, cerebral palsy, multiple sclerosis, cerebral, and spinal cord injury \[[@B2-toxins-12-00032]\]. The efficacy of BoNT therapy in migraine headaches, predicted by early investigators \[[@B3-toxins-12-00032]\], has been proven via two large, multicenter clinical trials leading to the approval of onabotulinumtoxinA for the treatment of chronic migraine \[[@B4-toxins-12-00032]\]. Animal and human studies have shown that the local injection of botulinum toxins has an analgesic effect and can relieve several forms of neuropathic pain \[[@B5-toxins-12-00032],[@B6-toxins-12-00032],[@B7-toxins-12-00032]\]. The data indicate an analgesic activity for BoNTs in a wide range of pain disorders that include both neuropathic and non-neuropathic pain.

In recent years, several publications have drawn attention to the utility of BoNT injections in cancer-related pain syndromes arising either by direct pressure from a neoplastic mass or from neuropathic pain at the site of cancer surgery or radiation \[[@B8-toxins-12-00032]\]. Aside from pain, BoNT injection into parotid or submaxillary glands has been shown to reduce symptoms such as sialorrhea resulting from gland injury as well as healing surgical complications such as fistula and sialocele \[[@B9-toxins-12-00032]\]. BoNT injections have been reported to relieve gustatory hyperhidrosis resulting from parotid and oral surgery in cancer patients \[[@B10-toxins-12-00032]\]. The limited literature also suggests that adding BoNT to the culture of cancer cell lines slows growth and mitotic activity of certain cancer cells and promotes apoptosis \[[@B11-toxins-12-00032]\].

This review is based on a literature search using the search engines of Pub Med, Ovid embrace, and Google Scholar from 1989 to 1 September 2019. The terms botulinum toxin, botulinum neurotoxin, onabotulinumtoxinA, incobotulinumtoxinA, abobotulinumtoxinA, and rimabotulinumtoxinB were crossed with cancer pain, postsurgical cancer pain, post-radiation cancer pain, salivary glands, sialorrhea, gustatory sweating, cancer cells, and cancer cell line. Book chapters that were written over the past 10 years focusing on the subject of botulinum toxin therapy in cancer patients were also reviewed. The inclusion criteria encompassed all articles found via those three afore-mentioned search engines using the above-mentioned search words. Inclusion required that the manuscript's abstract contain both words cancer (or neoplasm) and botulinum toxin (or botulinum neurotoxin) therapy. Manuscripts that did not have both cancer and botulinum toxin therapy noted in the abstract were excluded. Manuscripts with benign mass lesions were also excluded.

2. Results {#sec2-toxins-12-00032}
==========

The search identified 746 manuscripts from which 76 were relevant to the subject of botulinum toxins and cancer (see flow chart in [Figure 1](#toxins-12-00032-f001){ref-type="fig"}). After eliminating 12 duplications (due to an overlap between MedLine and Google Scholar), 64 manuscripts remained for final analysis. The collected data can be classified under 3 categories: (1) The role of botulinum toxins in post-radiation and post-surgical cancer pain; (2) the repairing and healing function of BoNT injections upon parotid gland damaged by radiation or surgery; and (3) the effect of botulinum toxins on cancer cell line, cell growth, and apoptosis.

2.1. Botulinum Neurotoxins Therapy for Post-Radiation And/Or Post-Surgical Cancer Pain {#sec2dot1-toxins-12-00032}
--------------------------------------------------------------------------------------

This heading includes six prospective clinical trials, four retrospective studies, one double blind placebo-controlled study, and six single case reports ([Table 1](#toxins-12-00032-t001){ref-type="table"}). A majority of patients had burning and searing pain along the region of fibrosis and keloid formation (neuropathic pain). Some also experienced additional local muscle spasms close to the scarred tissue affecting the neck and shoulder muscles. The most affected muscles were sternocleidomastoid, splenius capitus, trapezius, and levator scapulae. Injections were either subcutaneous (close or at the area of keloid and post-surgical scars, see [Figure 2](#toxins-12-00032-f002){ref-type="fig"}) or both subcutaneous and intramuscular.

A total of 10 of 11 studies used a standardized scale for pain measurement (Visual Analogue Scale: VAS) which in 9 of 10 demonstrated statistically significant improvement of local pain at 4--8 post-injection weeks compared to baseline (*p* \< 0.05) ([Table 1](#toxins-12-00032-t001){ref-type="table"}). Two studies included patient global impression of change (PGIC) in the evaluation, using a 7-grade scale ranging from "very unsatisfied" to "very satisfied". In both studies, patients expressed significant satisfaction with the results \[[@B18-toxins-12-00032],[@B20-toxins-12-00032]\]. Four studies used a scale for evaluating quality of life. Three of 4 demonstrated significant improvement of quality of life after BoNT-A (onaA and incoA) injection therapy \[[@B14-toxins-12-00032],[@B18-toxins-12-00032],[@B20-toxins-12-00032]\]. One study demonstrated significant reduction of daily opioid use after BoNT therapy \[[@B13-toxins-12-00032]\]. One prospective study provided long-term follow up of up to 82 months \[[@B20-toxins-12-00032]\]. Side effects consisted mainly of transient pain at the site of injection(s) and minor local bleeding. None of the 229 patients, reported in [Table 1](#toxins-12-00032-t001){ref-type="table"}, demonstrated any serious side effect following BoNT injections.

Clinical data from case reports includes six single case reports. One publication reported a 50 year-old man with adenocarcinoma of the soft palate, who following radiotherapy, developed trismus and myokymia of the masseter muscles. Trismus and myokymia improved after injection of 25 units of onaA into each masseter muscle \[[@B23-toxins-12-00032]\]. Two other manuscripts described improvement of central neuropathic pain in association with a mass lesion. One described a 55 year-women who developed severe burning pain and allodynia in the distribution of T1 dermatomes bilaterally following partial resection of an angioma at the C7--C8 region. Subcutaneous injection of onaA at 25 sites into T1 dermatomes (100 units on each sides) resulted in a marked reduction of neuropathic pain and allodynia. This effect was sustained with repeated injections over a follow up period of three years \[[@B24-toxins-12-00032]\]. A similar experience with central pain was reported by Nam et al. \[[@B25-toxins-12-00032]\], in a 62-year old man who had developed severe allodynia and neuropathic pain over the posterior aspect of the left thigh contralateral to a frontal lobe malignant brain tumor. A subcutaneous injection of onaA with a total dose of 100 units at 16 sites substantially improved the patient's neuropathic pain and allodynia over the affected region. In another patient, radiation of a left submandibular chondrosarcoma resulted in hyperactivity of the spinal accessory nerve and gradual painful hypertrophy of the left trapezius muscle. An injection of 90 units of onaA resulted in a substantial reduction of left shoulder pain and diminished the involuntary myokymic movements of the left trapezius muscle \[[@B26-toxins-12-00032]\]. Boukovalas et al. \[[@B27-toxins-12-00032]\] reported a patient with squamous cell carcinoma of the anterior mandible who, following mandibulectomy, bilateral neck dissection, and radiotherapy, gradually developed pain and tightness of the sternocleidomastoid and platysmal muscles associated with Raynaud phenomenon of the lower face. Injection of botulinum toxin (type and dose not mentioned) into the above-mentioned muscles improved painful muscle tightness and reduced the Raynaud phenomena. Schuler et al. \[[@B28-toxins-12-00032]\] described a 47-year old female who, at the scarred skin site of resected melanoma, developed severe neuropathic pain. Injection of onaA, 50 units in a grid-like pattern (injection sites were 1.5 cm apart), resulted in 50% reduction of pain four weeks after BoNT injection.

The duration of action of BoNT injections for pain relief in the above-mentioned studies was 3--6 months (mean 3.9 month). In most studies, the follow up was short term, not exceeding 6--12 months. In some cases, however, patients were followed-up for years with repeated injections. Two patients described in [Figure 1](#toxins-12-00032-f001){ref-type="fig"} were followed-up for 3 and 7 years (see figure legend). Nine of 11 studies reported no side effects. One study reported increased pain for a few days at the site of injection in one patient, which was followed by baseline pain improvement \[[@B14-toxins-12-00032]\]. One study reported the occurrence of a diffuse maculo-papular rash in one patient 2--3 days after the botulinum neurotoxin injection after which the rash disappeared over a month \[[@B20-toxins-12-00032]\].

2.2. Botulinum Neurotoxins Therapy for Post-Radiation or Postsurgical Damage to Parotid Gland {#sec2dot2-toxins-12-00032}
---------------------------------------------------------------------------------------------

This category includes six prospective clinical trials, 10 retrospective studies, and 12 single case reports ([Table 2](#toxins-12-00032-t002){ref-type="table"}). All prospective studies are open label. Botulinum toxin treatment was used for the remedy of post-parotidectomy complications such as gustatory hyperhidrosis (GH), post-parotidectomy sialorrhea, fistula, and sialocele formation.

The positive information of these studies has been supported by several case reports \[[@B45-toxins-12-00032],[@B46-toxins-12-00032],[@B47-toxins-12-00032],[@B48-toxins-12-00032],[@B49-toxins-12-00032],[@B50-toxins-12-00032],[@B51-toxins-12-00032],[@B52-toxins-12-00032],[@B53-toxins-12-00032],[@B54-toxins-12-00032],[@B55-toxins-12-00032],[@B56-toxins-12-00032]\]. Among these 12 case reports, six described healing of post-parotidectomy fistula and four reported on healing of sialocele. One case reported improvement of gustatory hyperhidrosis and another one reported improvement of post-parotidectomy sialorrhea. A total of 11 studies had used type-A and one had used type B toxin.

In these 11 studies, no serious side effects were reported. One study reported a patient on anticoagulation in whom a small hematoma developed at the site of injection \[[@B34-toxins-12-00032]\]. One study reported dry mouth as the only side effect \[[@B38-toxins-12-00032]\]. One study cited non-specified, minor issues limited to the site of injection \[[@B41-toxins-12-00032]\]. One study mentioned mild transient weakness of the upper lip in two patients \[[@B43-toxins-12-00032]\] and another study described transient weakness of orbicularis oris muscle in one patient \[[@B44-toxins-12-00032]\].

The clinical studies cited above investigating the analgesic effect of BoNTs in patients after surgery or radiation therapy and BoNT's healing effect on parotid glands injured by surgery or radiation strongly suggest the efficacy of BoNTs in cancer patients affected by surgical and radiation side effects. All three type-A FDA approved BoNTs seem to have analgesic effect in post-surgical and post-radiation pain. In case of parotid injury, at least one study ([Table 2](#toxins-12-00032-t002){ref-type="table"}) suggests that type B is also effective. Although anecdotal observations have demonstrated safety over 3 to 7 years of treatment (cases presented in [Figure 1](#toxins-12-00032-f001){ref-type="fig"}), the long term safety of BoNT therapy in cancer patients needs to be further investigated through controlled, prospective clinical trials.

2.3. The Effects of Botulinum Neurotoxins Injections on Malignant Tumors and Cancer Cell Line {#sec2dot3-toxins-12-00032}
---------------------------------------------------------------------------------------------

This category includes 14 studies. In three studies, investigators injected BoNT into a malignant tumor and demonstrated cellular apoptosis and reduction of tumor size \[[@B57-toxins-12-00032],[@B58-toxins-12-00032],[@B59-toxins-12-00032]\] ([Table 3](#toxins-12-00032-t003){ref-type="table"}). In another six studies, adding BoNT-A to cancer cell cultures reduced cell growth, induced apoptosis, and inhibited mitosis in various cancer cell lines: Prostate, breast, colon, and pancreatic tumors \[[@B60-toxins-12-00032],[@B61-toxins-12-00032],[@B62-toxins-12-00032],[@B63-toxins-12-00032],[@B64-toxins-12-00032],[@B65-toxins-12-00032]\]. In one study, transfection of insulin secreting cells by BoNT-A reduced insulin secretion, suggesting a potential for treatment of insulinomas \[[@B66-toxins-12-00032]\]. In another study, the addition of BoNT-A to Her2 positive breast cancer cell line increased Herceptin efficacy \[[@B67-toxins-12-00032]\]. In one study, authors reported no effect on prostate tumor growth and LNCaP and PC3 cancer cells after exposure to BoNT \[[@B68-toxins-12-00032]\]. In one study, increased tumor oxygenation after the injection of BoNT-A into hepatic sarcoma and fibrosarcoma suggested that the BoNT injection potentially made these tumors more susceptible to chemotherapy \[[@B69-toxins-12-00032]\]. In another study, the injection of onaA into one side of cancerous human prostate increased apoptosis on the injected side (compare to saline injected into other side) \[[@B70-toxins-12-00032]\].

3. Discussion {#sec3-toxins-12-00032}
=============

Botulinum neurotoxins exert their analgesic effect through two known mechanisms. The inhibitory effect of the BoNTs upon the release of acetylcholine at the neuromuscular junction is mostly responsible for the relief of pain caused by muscle spasms. In the case of neuropathic pain, it is currently believed that the analgesic effect of botulinum injections predominantly results from inhibition of pain neurotransmitters both at peripheral and at central sensory levels \[[@B5-toxins-12-00032],[@B6-toxins-12-00032],[@B71-toxins-12-00032],[@B72-toxins-12-00032]\]. The peripheral injection of botulinum toxin-A into the muscle or close to peripheral nerve endings reduces the release of calcitonin gene related peptide, a major pain transmitter from trigeminal ganglion \[[@B73-toxins-12-00032]\]. Direct exposure of dorsal root ganglia to botulinum toxin-A significantly reduces the thermal sensitivity in the animal model of thermal pain \[[@B74-toxins-12-00032]\]. In the formalin pain model, injection botulinum toxin B into the rat's paw reduced substance P release from ipsilateral sensory spinal neurons and prevented spinal sensory neuron activation (c-Fos) which occurred after formalin injection \[[@B75-toxins-12-00032]\]. Injection of botulinum toxins into mice hind paw reduces glutamate release from spinal sensory neurons \[[@B76-toxins-12-00032]\]. Intra-articular injection of botulinum toxin in animal models of pain reduces upregulation of transient receptor potential cation channel subfamily V member 1 (TrpV1), a protein closely associated with pain pathophysiology \[[@B77-toxins-12-00032]\]. A central analgesic function for botulinum toxins has been suggested by studies that have shown the presence of cleaved SNAP-25 in medullary and midbrain sensory regions following the peripheral injection of botulinum toxins \[[@B78-toxins-12-00032],[@B79-toxins-12-00032]\]. Further suggestion for central effects of BoNTs comes from the studies that have demonstrated bilateral improvement of pain sensations after the unilateral injection of botulinum toxin in animal models of diabetic neuropathy and acidic saline injection \[[@B80-toxins-12-00032],[@B81-toxins-12-00032]\]. The analgesic effect of BoNTs results from their direct and indirect effects since patients experience analgesia prior to the muscle relaxation \[[@B82-toxins-12-00032]\].

Pain is a common symptom in cancer patients and when present often impairs the patient's quality of life \[[@B83-toxins-12-00032]\]. Approximately 20--60% of the patients with breast cancer and 30% of the patients with head and neck cancer experience chronic pain localized to the site of radiation or surgery \[[@B84-toxins-12-00032]\]. Post-radiation/surgical pain may be treated with the topical application of a hyaluronic acid, calendula officinalis, trolamine, and lidocaine patch \[[@B85-toxins-12-00032],[@B86-toxins-12-00032]\]. However, sustained relief from pain happens only in 25% of the patients using these remedies \[[@B87-toxins-12-00032]\]. Potent systemic analgesic agents such as opioids provide pain relief in many patients but the development of undesirable side effects including nausea, somnolence, constipation, and addiction complicates their use \[[@B88-toxins-12-00032]\]. Botulinum toxin treatment has two major advantages over these pharmacological remedies. Firstly, the effects of the BoNT-A and B injection lasts 3--6 months. Secondly, the BoNT injection has fewer side effects and is safer when compared to potent analgesic agents. Lack of any serious side effect in the studies cited above supports this statement.

Gustatory hyperhidrosis (Frey syndrome) can be congenital or acquired. Acquired gustatory hyperhidrosis results from injury to the parotid gland or face as well as conditions such as diabetic autonomic neuropathy. Gustatory hyperhidrosis after parotidectomy results from the aberrant innervation of sweat glands from parasympathetic nerves of the parotid region. Facial sweating during chewing and eating is often a cause of social embarrassment. Gustatory hyperhidrosis (GH) is common after parotidectomy and about half of the patients complained of this symptom after surgery \[[@B89-toxins-12-00032]\]. Botulinum neurotoxins via blocking acetylcholine release at autonomic synapses are highly effective in treatment of autonomic dysfunctions such as sialorrhea and hyperhidrosis \[[@B90-toxins-12-00032]\]. In a meta-analysis of literature on Frey syndrome (multiple etiologies) treated with BoNTs, Xie et al. found the effectiveness of BoNT therapy to be present in 98% of the patients \[[@B10-toxins-12-00032]\].

Fistula with sialorrhea and sialocele (entrapped saliva with cyst formation) are two common complications of parotidectomy. Treatment of post-parotidectomy fistula consist of pressure dressing, systemic anticholinergic drugs, suction drain insertion, tympanic neurectomy, and surgery \[[@B91-toxins-12-00032]\]. Overall, the results of the above mentioned surgical and medical strategies in the treatment of parotid fistula is disappointing \[[@B92-toxins-12-00032]\]. Furthermore, side effects of anticholinergic therapy such as memory loss, blurring of vision, dryness of the mouth, and urinary dysfunction are not well tolerated, especially in the elderly. Botulinum toxin injections provides a safe and effective way to suppress sialorrhea and to help heal the fistula.

4. Conclusions {#sec4-toxins-12-00032}
==============

The studies of botulinum toxins in post-surgical and post-radiation pain indicated that the local injection of BoNT improved neuropathic pain and local muscle spasm at/or close to the site of surgery and radiation. The proof of efficacy of botulinum toxin therapy in this form of cancer-related pain, however, awaits the results of blinded and placebo-controlled studies. The same conclusion applies to the use of botulinum neurotoxins in gustatory hyperhidrosis and in the management of post-parotidectomy fistula and sialocele where all open-label studies suggest efficacy. The positive effect of BoNTs on different cancer cell lines and their direct effects upon certain cancerous tumors is encouraging. More studies are necessary to verify these results and if verified to devise a methodology through which BoNT injections can safely be used for the treatment of certain human cancers.
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![Flow chart of the reviewed manuscripts on cancer and botulinum neurotoxin therapy.](toxins-12-00032-g001){#toxins-12-00032-f001}

![Post-surgical and post-radiation pain treated with BoNT. Example of two patients. From Jabbari B. Botulinum Toxin Treatment in Pain Disorders. Springer, New York 2015. Printed with permission from the publisher. (**A**) A 47-year-old man had undergone right neck dissection and radiotherapy for cancer of the tongue and cervical adenopathy 6 years prior to visiting the Yale clinic. A year following surgery and radiotherapy, severe pain (VAS 9--10, both sharp and deep) developed over the right side of the neck which was mostly felt below the mandible and anterior to the angle of the jaw. Injecting onabotulinumtoxinA into the areas designated by X on the figure, (30, 30, and 20 units) reduced the pain significantly (VAS 1) within a week after injection. He remained responsive and satisfied (assessed by PGIC) receiving injections every 4--6 months over 7 years of follow-up. (**B**) A 48-year old man with squamous cell carcinoma of piriform sinus had supraglottic laryngectomy. Two years following neck dissection and radiotherapy, he developed severe pain (VAS 9) over the left side of the neck. The pain was deep as well as sharp and superficial. Injection of onabotulinumtoxinA, 20 units into each superficial pain region (Xs around the jaw) and 30 units into nearby posteriorly located muscles (splenius and trapezius) designated by X reduced the pain to VAS 0--1 level. The total dose was 200 units. The patient enjoyed pain relief with repeat injections over the 3 years of follow-up. Drawings courtesy of Damoun Safarpour M.D.](toxins-12-00032-g002){#toxins-12-00032-f002}

toxins-12-00032-t001_Table 1

###### 

Published studies on the effect of botulinum neurotoxins (BoNT) on local pain resulting from radiation and/or surgery \*.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                Pts Study   Toxin    Dose Units   Treatment                                                Location of Cancer   Primary Outcome                            Result
  ------------------------------------------------------ ----------- -------- ------------ -------------------------------------------------------- -------------------- ------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Van Daele et al., 2002 \[[@B12-toxins-12-00032]\]      6\          OnaA     20--25       Radiation chemotherapy                                   Head and neck        Pain VAS                                   Complete pain relief in four of six patients. Significant improvement of quality of life using SF36, EQ-5D scales
                                                         Retro                                                                                                                                                      

  Layeeque et al., 2004 \[[@B13-toxins-12-00032]\]       48\         OnaA     100          Mastectomy, assessed for pain after expander placement   Breast               \(1\) Pain assessed by VAS\                Less pain in BoNT group (*p* \< 0.00001)\
                                                         Pro                                                                                                             (2) Narcotic use                           Less narcotic use in BoNT group (*p* \< 0.0001)

  Vasan et al., 2004 \[[@B14-toxins-12-00032]\]          16\         AboA     100 to 320   Surgery                                                  Head and neck        Pain (VAS- days 3 and 4 weeks), global.\   Significant pain reduction (*p* = 0.05);\
                                                         Pro                                                                                                             Quality of life                            Quality of life improved (*p* = 0.7)

  Wittekindt et al., 2006 \[[@B15-toxins-12-00032]\]     23\         OnaA     60--120\     Radiation;\                                              Head and neck        Pain\                                      Significant reduction of pain (\<0.05)
                                                         Pro                  160--240     surgery                                                                       VAS:\                                      
                                                                                                                                                                         28 weeks                                   

  Hartl et al., 2008 \[[@B16-toxins-12-00032]\]          19\         OnaA\    50\          Chemotherapy;\                                           Head and neck        Pain: (VAS)\                               Improved\
                                                         Pro         AboA     250          radiation                                                                     Function:\                                 pain (*p* = 0.02)\
                                                                                                                                                                         At 4 weeks                                 Function (*p* = 0.04)

  Stubblefield et al., 2008 \[[@B17-toxins-12-00032]\]   23\         OnaA     25--200      Radiation;\                                              Head, neck, breast   Pain (VAS)                                 Pain improved in Improved in 85% of patients
                                                         Retro                             surgery                                                                                                                  

  Mittal et al., 2012 \[[@B18-toxins-12-00032]\]         7\          OnaA     100          Radiation;\                                              Head, neck, breast   Pain (VAS)\                                VAS: Six of seven patients improved: *p* \< 0.05\
                                                         Retro                             surgery                                                                       PGIC\                                      PGIC: Six of seven, very satisfied\
                                                                                                                                                                         At 4 weeks                                 QoL: Six of seven improved (*p* \< 0.05)

  Bach et al., 2012 \[[@B19-toxins-12-00032]\]           9\          OnaA     100--400     Radiation and\                                           Head and neck        Pain (VAS) and FDSNP at 4 weeks            Both pain and FDSNP improved\
                                                         Pro                               surgery                                                                                                                  (*p* \< 0.01)

  Rostami et al., 2014 \[[@B20-toxins-12-00032]\]        12\         IncoA    100          Radiation and\                                           Head neck breast     Pain (VAS) and PGIC at week 6              VAS improved (*p* \< 0.05)\
                                                         Pro                               surgery                                                                                                                  PGIC: Very satisfied\
                                                                                                                                                                                                                    QoL improved in 38% of patients (*p* \< 0.05)

  De Groef et al. 2018 \[[@B21-toxins-12-00032]\]        50\         onaA     100          Surgery                                                  Breast               Pain measured by VAS                       Pain reduction 60% in the BoNT and 40% in saline group (statistically ns)
                                                         DBPC                                                                                                                                                       

  Mailly et al., 2019 \[[@B22-toxins-12-00032]\]         16\         incoA\   20\          Radiation and surgery                                    Head and neck        Pain (VAS)                                 VAS improved\
                                                         Retro       aboA     40                                                                                                                                    *p* \< 0.01
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Case reports are not included. onaA: OnabotulinumtoxinA; aboA: AbobotulinumtoxinA; incoA: IncobotulinumtoxinA; VAS: Visual Analogue Scale; PGIC: Patient Global Impression of Change; FDSNP: Functional Disability Scale for Neck Pain; Pro: Prospective; Retro: Retrospective; DBPC: double-blind, placebo-controlled; QoL: Quality of Life.

toxins-12-00032-t002_Table 2

###### 

BoNT therapy for post-parotidectomy gustatory hyperhidrosis, fistula, sialocele formation, and for post-parotidectomy sialorrhea.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                   Design   Pts \#   Clinical Problem                                                   Injection\      Toxin and Dose                       Result
                                                                                                                                                 Site                                                 
  --------------------------------------------------------- -------- -------- ------------------------------------------------------------------ --------------- ------------------------------------ ------------------------------------------------------------------------
  Laskawi et al., 2013 \[[@B29-toxins-12-00032]\]           R        10       Post-parotidectomy fistula                                         Parotid gland   OnaA\                                Treated within 6 weeks of surgery: Fistulas healed in 9 of 10 patients
                                                                                                                                                                 30--50 units                         

  Marchese-Ragona et al., 2006 \[[@B30-toxins-12-00032]\]   R        3        Post-parotidectomy fistula                                         Parotid gland   OnaA\                                Complete healing of fistula with follow ups 12,18, and 14 months
                                                                                                                                                                 15--20 units                         

  Nolte et al., 2004 \[[@B31-toxins-12-00032]\]             P        20       Gustatory sweating after parotidectomy                             Facial skin     OnaA\                                Complete loss of sweating for 12 months
                                                                                                                                                                 3 units/cm                           

  Kuttner et al., 2001 \[[@B32-toxins-12-00032]\]           R        8        GH after parotidectomy                                             Face            BoNT-A\                              Stopped facial sweating within one week
                                                                                                                                                                 0.5 units/cm                         

  Vargas et al., 2000 \[[@B33-toxins-12-00032]\]            P        4        Post-parotidectomy\                                                Parotid gland   OnaA\                                Total resolution in 4 weeks in all patients
                                                                              sialocele-pain                                                                     30--50 units                         

  Steffen et al., 2014 \[[@B34-toxins-12-00032]\]           R        25       Head and neck cancer\                                              Parotid gland   OnaA and incoA: Par: 30 U SM: 20 U   FHS: 11 of 19 improved.\
                                                                              FHS: (19)\                                                                                                              Fistula: 4 of 6 improved
                                                                              Fistula (6)                                                                                                             

  Machese et al., 2008 \[[@B35-toxins-12-00032]\]           R        8        Head and neck cancer sialorrhea: 6, fistula: 1, and sialocele: 1   Parotid gland   AboA:\                               Fistulas healed.\
                                                                                                                                                                 100 U                                Sialorrhea stopped

  Eckardt et al., 2003 \[[@B36-toxins-12-00032]\]           R        33       GH after parotidectomy                                             Face            OnaA\                                Facial sweating disappeared within a week after injections
                                                                                                                                                                 16 to 80 units                       

  Cantarella and Barbieri\                                  R        7        GH after parotidectomy                                             Face            RimaB\                               Cessation of sweating in 6 of 7 patients 4 weeks after injection
  \[[@B37-toxins-12-00032]\]                                                                                                                                     2200 units                           

  Matos Dias et al., 2008 \[[@B38-toxins-12-00032]\]        R        10       GH after parotidectomy                                             Face            Ona-A\                               Sweating stopped
                                                                                                                                                                 38 units                             

  Hatrl et al., 2008 \[[@B39-toxins-12-00032]\]             R        7        GH after parotidectomy                                             Face            BoNT-A                               Sweating and quality of life improved

  Pomprasit et al., 2007 \[[@B40-toxins-12-00032]\]         P        9        GH after Parotidectomy                                             Face            Ona-A\                               Sweating stopped in 5 and reduced in 4
                                                                                                                                                                 10.6 units                           

  Cavalot et al., 2000 \[[@B41-toxins-12-00032]\]           P        40       GH after parotidectomy                                             Face            Ona-A, 2.5/cm^2^                     100% response in severe group, 72% response in moderate group

  Von Lindern et al., 2000 \[[@B42-toxins-12-00032]\]       R        7        GH after parotidectomy                                             Face            Ona-A                                Sweating stopped after BoNT injection

  Laccourreye et al., 1998 \[[@B43-toxins-12-00032]\]       P        14       GH after parotidectomy                                             Face            Ona-A                                All showed total cessation of sweating

  Bjerkhoel et al., 1997 \[[@B44-toxins-12-00032]\]         P        15       GH after parotidectomy                                             Face            Ona-A                                Total cessation of facial sweating in 13 patients
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Case reports are not included for salivary gland problems related to cancer surgery or cancer irradiation. R: Retrospective; P: Prospective; onaA: OnabotulinumtoxinA; incoA: IncobotulinumtoxinA; aboA: AbobotulinumtoxinA; FHS: Functional hypersalivation; Par: Parotid, SM: Submandibular.

toxins-12-00032-t003_Table 3

###### 

In vivo and in vitro effects of BoNT injection on malignant tumors and cancer cell lines.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                 Study Type             Type of Cells or Tissue                 Study Design                                                                                     Results
  ------------------------------------------------------- ---------------------- --------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------
  Vezdrevanis\                                            In vivo                Prostatic cancer                        Injected BoNT into prostate                                                                      Tumor size reduction
  2011 \[[@B57-toxins-12-00032]\]                                                                                                                                                                                         

  Ulloa et al., 2015 \[[@B58-toxins-12-00032]\]           In vivo                Glioblastoma cells                      Cells with or without transfection by BoNT-C1 injected into mice striatum                        By BoNT-C1 blocks the growth of Glioblastoma cells via blocking Syntaxin1

  He et al.,\                                             In vivo                Mice with pancreatic tumor              Injected onaA or saline into tumor                                                               Reduced tumor size;\
  2016 \[[@B59-toxins-12-00032]\]                                                                                                                                                                                         increased apoptosis

  Karsenty et al., 2009 \[[@B60-toxins-12-00032]\]        In vitro               Prostate LNCaP and PC-3 cell lines      LNCaP and PC-3 cell lines were exposed to onaA                                                   OnaA inhibited LNCasP cell proliferation; had no effect on PC-3 cell

  Nam et al., 2012 \[[@B61-toxins-12-00032]\]             In vitro               Breast and colorectal cancer            PLC-γl-transformed cells were exposed to BoNT-A (difficile)                                      Caused apoptosis and mitotic inhibition

  Proietti et al., 2012 \[[@B62-toxins-12-00032]\]        In vitro               Prostate LNCaP and PC-3 cell lines      Prostate cancer cell lines were exposed to incoA                                                 Tumor cell growth slowed down probably due to toxin effect on SV2 receptors

  Bandala et al., 2013 \[[@B63-toxins-12-00032]\]         In vitro               Breast T47D cancer cells                Breast T47D cancer cells were exposed to diverse dilutions of BoNT                               BoNT via caspase 3, slow down the growth of T47d cells and caused apoptosis

  Bandala et al., 2015 \[[@B64-toxins-12-00032]\]         In vitro               Breast cancer cell line                 Added BoNT-A to breast cancer cell line                                                          BoNT-A diminished SV2 protein on the surface of breast cancer cells

  Rust et al., 2016 \[[@B65-toxins-12-00032]\]            In vitro               Human neuroblastoma cells               Added BoNT-C to human neuroblastoma cell culture                                                 Apoptosis of neuroblastoma cells

  Huang et al.,\                                          Invitro                Insulin secreting HIT-T15 cells         Insulin secreting cells were transfected by BoNT-A                                               Marked reduction of insulin secretion- potential to treat insulinoma
  1998 \[[@B66-toxins-12-00032]\]                                                                                                                                                                                         

  Hajighasemlou et al., 2015 \[[@B67-toxins-12-00032]\]   In vitro               Her2 positive breast cancer cell line   Assessed the effect of BoNT-A on Her2 positive cells responsive to Herceptin                     Herceptin efficacy significantly improved

  Cheng et al., 2013 \[[@B68-toxins-12-00032]\]           In vitro and in vivo   Prostate cancer cell line in\           LNCaP and PC3 cancer cells were exposed to 1 to 10 units of onaA                                 No effect on tumor growth in LNCaP and PC3 cancer cells
                                                                                 Mice                                                                                                                                     

  Ansiaux et al., 2006 \[[@B69-toxins-12-00032]\]         In vivo                Fibrosarcoma, hepatosarcoma             BoNT-A injected into the tumor                                                                   Increased oxygenation of the tumor and made it more susceptible to chemo and radiotherapy

  Coarfa et al., 2017 \[[@B70-toxins-12-00032]\]          In vivo                Prostate of 250 nude mice\              Effect of onaA versus saline injection into cancer cells implanted into rodent's prostate\       Increased apoptosis; slowed cancer progression\
                                                                                 Four human cancerous prostates          Assessed the effect of onaA versus saline injection in cancerous prostate before prostatectomy   Increased apoptosis in ona-A injected side of prostate
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OnaA: OnabotulinumtoxinA (Botox). IncoA: IncobotulinumtoxinA (Xeomin).
